Literature DB >> 10881897

Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study.

H Furrer, M Opravil, E Bernasconi, A Telenti, M Egger.   

Abstract

Discontinuation of primary prophylaxis against toxoplasma encephalitis was studied in 199 HIV-1-infected patients on antiretroviral combination treatment who had experienced a sustained increase in their CD4 count. During a follow-up of 272 person-years, no cases of toxoplasma encephalitis arose.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10881897     DOI： 10.1016/s0140-6736(00)02407-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  11 in total

1.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Novel Approaches To Kill Toxoplasma gondii by Exploiting the Uncontrolled Uptake of Unsaturated Fatty Acids and Vulnerability to Lipid Storage Inhibition of the Parasite.

Authors:  Sabrina J Nolan; Julia D Romano; John T Kline; Isabelle Coppens
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  A single Na+-Pi cotransporter in Toxoplasma plays key roles in phosphate import and control of parasite osmoregulation.

Authors:  Beejan Asady; Claudia F Dick; Karen Ehrenman; Tejram Sahu; Julia D Romano; Isabelle Coppens
Journal:  PLoS Pathog       Date:  2020-12-31       Impact factor: 6.823

Review 5.  Central nervous system infections in individuals with HIV-1 infection.

Authors:  Arunima Mamidi; Joseph A DeSimone; Roger J Pomerantz
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

6.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

Review 7.  Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective.

Authors:  Anna Thorner; Eric Rosenberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era.

Authors:  Hansjakob Furrer
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.663

Review 9.  Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management.

Authors:  E N Janoff; P D Smith
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

10.  Immunoinformatic Analysis of Calcium-Dependent Protein Kinase 7 (CDPK7) Showed Potential Targets for Toxoplasma gondii Vaccine.

Authors:  Ali Taghipour; Sanaz Tavakoli; Mohamad Sabaghan; Masoud Foroutan; Hamidreza Majidiani; Shahrzad Soltani; Milad Badri; Ali Dalir Ghaffari; Sheyda Soltani
Journal:  J Parasitol Res       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.